Levowin Tablet contains Levofloxacin 500 mg, a broad-spectrum fluoroquinolone antibiotic effective against a wide range of gram-positive and gram-negative bacterial infections. It acts by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication, transcription, repair, and recombination, leading to bacterial cell death. Levowin is indicated for the treatment of respiratory tract infections such as community-acquired pneumonia, chronic bronchitis exacerbations, and sinusitis; urinary tract infections including complicated and uncomplicated cases; skin and soft tissue infections; and certain types of prostatitis. It is also utilized in the management of anthrax exposure and plague. The tablet is administered orally, with dosing tailored according to the severity of infection, renal function, and patient-specific factors. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal pain, as well as central nervous system effects like headache and dizziness. Caution is advised in patients with a history of tendon disorders related to fluoroquinolone use, and it is contraindicated in individuals with known hypersensitivity to Levofloxacin or other quinolones. Use during pregnancy and lactation should be avoided unless clearly necessary. Levowin Tablet should be prescribed and used under medical supervision to ensure efficacy and minimize resistance development.